Journal of Comprehensive Pediatrics

Published by: Kowsar

Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder

Nasrin Dodangi 1 , Nastaran Habibi 1 , * and Ali Nazeri astaneh 1
Authors Information
1 Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran
Article information
  • Journal of Comprehensive Pediatrics: November 01, 2015, 6 (4); e27482
  • Published Online: November 23, 2015
  • Article Type: Research Article
  • Received: April 27, 2015
  • Revised: October 25, 2015
  • Accepted: November 14, 2015
  • DOI: 10.17795/compreped-27482

To Cite: Dodangi N, Habibi N, Nazeri astaneh A. Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder, J Compr Ped. 2015 ; 6(4):e27482. doi: 10.17795/compreped-27482.

Copyright © 2015, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 2013; : 466-71
  • 2. Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep. 2008; 10(5): 424-31[PubMed]
  • 3. Sadock BJ, Sadock VA. Kaplan and Sadock's comprehensive textbook of psychiatry . 2005;
  • 4. Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004; 19(3): 151-80[DOI][PubMed]
  • 5. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44(5): 428-33[DOI][PubMed]
  • 6. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009; 11(3): 203-26[DOI][PubMed]
  • 7. Findling RL, Greenhill LL, McNamara NK, Demeter CA, Kotler LA, O'Riordan MA, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007; 17(4): 433-45[DOI][PubMed]
  • 8. Mukaddes NM, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci. 2004; 58(1): 92-5[PubMed]
  • 9. Green WH. Child and Adolescent Clinical Psychopharmacology. 2007; : 716
  • 10. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005; 20(5): 327-41[DOI][PubMed]
  • 11. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009; 23(6): 523-41[DOI][PubMed]
  • 12. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry. 2007; 19(2): 125-32[DOI][PubMed]
  • 13. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009; 5: 23-31[PubMed]
  • 14. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol. 2012; 22(1): 48-55[DOI][PubMed]
  • 15. Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol. 2007; 17(1): 121-7[DOI][PubMed]
  • 16. Desarkar P, Das A, Sinha VK. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry. 2006; 15(8): 496-9[DOI][PubMed]
  • 17. Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005; 4(6): 987-93[DOI][PubMed]
  • 18. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007; 30(5): 437-55[PubMed]
  • 19. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007; 49(3): 146-53[DOI][PubMed]
  • 20. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007; 23(1): 175-84[DOI][PubMed]
  • 21. Dulkan MK, Mina K. Dulkan's Textbook of Child and Adolescent Psychiatry. 2010;
  • 22. Ghanizadeh A, Mohammadi MR, Yazdanshenas A. Psychometric properties of the Farsi translation of the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version. BMC Psychiatry. 2006; 6: 10[DOI][PubMed]
  • 23. Shahrivar Z, Kousha M, Moallemi S, Tehrani-Doost M, Alaghband-Rad J. The reliability and validity of kiddie-schedule for affective disorders and schizophrenia- present and lifetime. Child Adolescent Ment Health. 2010; 15(2): 97-102[DOI]
  • 24. Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985; 21(4): 809-43[PubMed]
  • 25. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998; 26(4): 257-68[PubMed]
  • 26. Reynolds CR, Richmond BO. What I Think and Feel: a revised measure of Children's Manifest Anxiety. J Abnorm Child Psychol. 1997; 25(1): 15-20[PubMed]
  • 27. Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull. 1985; 21(4): 995-8[PubMed]
  • 28. Rajabi G,H,R. An investigation of reliability and validity of child depression inventory in 13 to 15 years old adolescents. J Psychol Education. 2007; 37: 23-46
  • 29. Taghavi S,M,R. The normalization of revised children manifest anxiety scale (RCMAS) for students in Shiraz. J Social Sciences Hum Shiraz. 2006; 22(4): 179-88
  • 30. Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord. 2009; 13(1): 95-6[DOI][PubMed]
  • 31. Niederhofer H. Duloxetine May Improve Some Symptoms of Attention Deficite/Hyperactivity Disorder ,Prim Care Companion . J Clin Psychiatry. 2010; 12(2)
  • 32. Mahmoudi-Gharaei J, Dodangi N, Tehrani-Doost M, Faghihi T. Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study. Hum Psychopharmacol. 2011; 26(2): 155-60[DOI][PubMed]
  • 33. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002; 159(11): 1896-901[DOI][PubMed]
  • 34. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001; 108(5)[PubMed]
  • 35. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1996; 6(4): 241-50[PubMed]
  • 36. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002; 63(4): 308-15[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments